Propionate and butyrate counteract renal damage and progression to chronic kidney disease
Nephrology Dialysis Transplantation · 20.12.2024 · 40 (1) · 133-150
DOI: 10.1093/ndt/gfae118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 24.05.2024. Verfasst von Viviana Corte-Iglesias und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Asturias, Spain. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Butyrates, Propionates, Disease Progression. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union, Adquisición de equipamiento e Infraestructuras científico-técnicas.
Abstract (Originalsprache)
Background
Short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate, are produced by gut microbiota through fermentation of complex carbohydrates that cannot be digested by the human host. They affect gut health and can contribute at the distal level to the pathophysiology of several diseases, including renal pathologies.
Methods
SCFA levels were measured in chronic kidney disease (CKD) patients (n = 54) at different stages of the disease, and associations with renal function and inflammation parameters were examined. The impact of propionate and butyrate in pathways triggered in tubular cells under inflammatory conditions was analysed using genome-wide expression assays. Finally, a pre-clinical mouse model of folic acid–induced transition from acute kidney injury to CKD was used to analyse the preventive and therapeutic potential of these microbial metabolites in the development of CKD.
Results
Faecal levels of propionate and butyrate in CKD patients gradually reduce as the disease progresses, and do so in close association with established clinical parameters for serum creatinine, blood urea nitrogen and the estimated glomerular filtration rate. Propionate and butyrate jointly downregulated the expression of 103 genes related to inflammatory processes and immune system activation triggered by tumour necrosis factor-α in tubular cells. In vivo, the administration of propionate and butyrate, either before or soon after injury, respectively, prevented and slowed the progression of damage. This was indicated by a decrease in renal injury markers, the expression of pro-inflammatory and pro-fibrotic markers, and recovery of renal function over the long term.
Conclusions
Propionate and butyrate levels are associated with a progressive loss of renal function in CKD patients. Early administration of these SCFAs prevents disease advancement in a pre-clinical model of acute renal damage, demonstrating their therapeutic potential independently of the gut microbiota.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Asturias, Spain.
- Kidney Disease Spanish Network, RICORS2040, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Nephrology, Hospital Universitario San Agustin, Avilés, Spain.
- Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Villaviciosa, Spain.
- Diet, Human Microbiota and Health Group, Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Asturias, Spain.
Förderung
- Instituto de Salud Carlos III
- European Union
- Adquisición de equipamiento e Infraestructuras científico-técnicas
- NextGenerationEU
- Mechanism for Recovery and Resilience (MRR)/RETC
- PCTI-Plan de Ciencia
- Tecnología e Innovación 2021-2023 del Gobierno del Principado de Asturias/FEDER
- Department of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country
Zitieren
APA
Corte-Iglesias, V., Saiz, M. L., Andrade-Lopez, A. C., Salazar, N., Bernet, C. R., Martin-Martin, C., Borra, J. M., Lozano, J. J., Aransay, A. M., Diaz-Corte, C., Lopez-Larrea, C., & Suarez-Alvarez, B. (2024). Propionate and butyrate counteract renal damage and progression to chronic kidney disease. Nephrology Dialysis Transplantation, 40(1), 133-150. https://doi.org/10.1093/ndt/gfae118
Vancouver
Corte-Iglesias V, Saiz ML, Andrade-Lopez AC, Salazar N, Bernet CR, Martin-Martin C, et al. Propionate and butyrate counteract renal damage and progression to chronic kidney disease. Nephrology Dialysis Transplantation. 2024;40(1):133-150. doi:10.1093/ndt/gfae118
BibTeX
@article{CorteIglesias2024,
author = {Corte-Iglesias, Viviana and Saiz, Maria Laura and Andrade-Lopez, Ana Cristina and Salazar, Nuria and Bernet, Cristian Ruiz and Martin-Martin, Cristina and Borra, Jesús Martinez and Lozano, Juan-Jose and Aransay, Ana M and Diaz-Corte, Carmen and Lopez-Larrea, Carlos and Suarez-Alvarez, Beatriz},
title = {Propionate and butyrate counteract renal damage and progression to chronic kidney disease},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
volume = {40},
number = {1},
pages = {133--150},
doi = {10.1093/ndt/gfae118}
}
EUVIMED